EA201100301A1 - Daa-пиридин в качестве лиганда периферического бензодиазепинового рецептора для диагностической визуализации и фармацевтического лечения - Google Patents
Daa-пиридин в качестве лиганда периферического бензодиазепинового рецептора для диагностической визуализации и фармацевтического леченияInfo
- Publication number
- EA201100301A1 EA201100301A1 EA201100301A EA201100301A EA201100301A1 EA 201100301 A1 EA201100301 A1 EA 201100301A1 EA 201100301 A EA201100301 A EA 201100301A EA 201100301 A EA201100301 A EA 201100301A EA 201100301 A1 EA201100301 A1 EA 201100301A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- daa
- ligand
- pyridine
- pharmaceutical treatment
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Addiction (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Vascular Medicine (AREA)
- Radiology & Medical Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pyridine Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nuclear Medicine (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Настоящее изобретение относится к новым соединениям, пригодным для введения радиоактивных изотопов или которые уже меченыF, способам получения такого соединения, композициям, содержащим такие соединения, наборам, содержащим такие соединения или композиции, и применениям таких соединений, композиций или наборов для лечения и для диагностической визуализации путем позитронно-эмиссионной томографии (PET).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08161903 | 2008-08-06 | ||
PCT/EP2009/005651 WO2010015387A1 (en) | 2008-08-06 | 2009-08-05 | Daa-pyridine as peripheral benzodiazepine receptor ligand for diagnostic imaging and pharmaceutical treatment |
Publications (2)
Publication Number | Publication Date |
---|---|
EA201100301A1 true EA201100301A1 (ru) | 2011-12-30 |
EA018650B1 EA018650B1 (ru) | 2013-09-30 |
Family
ID=41198601
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201100301A EA018650B1 (ru) | 2008-08-06 | 2009-08-05 | Daa-пиридин в качестве лиганда периферического бензодиазепинового рецептора для диагностической визуализации и фармацевтического лечения |
Country Status (24)
Country | Link |
---|---|
US (1) | US20110200535A1 (ru) |
EP (1) | EP2321279B1 (ru) |
JP (1) | JP2011529929A (ru) |
KR (1) | KR20110041559A (ru) |
CN (1) | CN102112448B (ru) |
AR (1) | AR073263A1 (ru) |
AU (1) | AU2009278279B2 (ru) |
BR (1) | BRPI0917099A2 (ru) |
CA (1) | CA2733105A1 (ru) |
CL (1) | CL2011000237A1 (ru) |
CO (1) | CO6351715A2 (ru) |
CR (1) | CR20110064A (ru) |
DO (1) | DOP2011000046A (ru) |
EA (1) | EA018650B1 (ru) |
EC (1) | ECSP11010808A (ru) |
IL (1) | IL210597A0 (ru) |
MX (1) | MX2011001406A (ru) |
NZ (1) | NZ590923A (ru) |
PE (1) | PE20110226A1 (ru) |
SV (1) | SV2011003830A (ru) |
TW (1) | TW201010734A (ru) |
UY (1) | UY32037A (ru) |
WO (2) | WO2010015340A1 (ru) |
ZA (1) | ZA201101700B (ru) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL2114873T3 (pl) | 2006-12-26 | 2013-08-30 | Lantheus Medical Imaging Inc | N-[3-Bromo-4-(3-[18F]fluoropropoksy)-benzylo]-guanidyna do obrazowania unerwienia serca |
WO2010015340A1 (en) * | 2008-08-06 | 2010-02-11 | Bayer Schering Pharma Aktiengesellschaft | Daa-pyridine as peripheral benzodiazepine receptor ligand for diagnostic imaging and pharmaceutical treatment |
GB0904715D0 (en) * | 2009-03-19 | 2009-05-06 | Ge Healthcare Ltd | Aryloxyanilide derivataives |
WO2011110488A1 (en) * | 2010-03-09 | 2011-09-15 | Bayer Pharma Aktiengesellschaft | A novel pet imaging agent of amyloid plaques and its precursor |
MX367382B (es) * | 2010-05-11 | 2019-08-19 | Lantheus Medical Imaging Inc | Composiciones, metodos y sistemas para la sintesis y el uso de agentes trazadores. |
DK2571503T3 (en) | 2010-05-14 | 2015-04-20 | Dana Farber Cancer Inst Inc | COMPOSITIONS AND THEIR USE IN THE TREATMENT OF NEOPLASIA, INFLAMMATORY DISEASE AND OTHER DISORDERS |
US9301962B2 (en) | 2010-05-14 | 2016-04-05 | Baylor College Of Medicine | Male contraceptive compositions and methods of use |
CN105582014B (zh) * | 2010-05-14 | 2019-06-14 | 达那-法伯癌症研究所 | 用于治疗白血病的组合物和方法 |
SG2014013767A (en) | 2011-09-09 | 2014-05-29 | Lantheus Medical Imaging Inc | Compositions, methods, and systems for the synthesis and use of imaging agents |
MX2016001037A (es) | 2013-07-25 | 2016-11-10 | Dana Farber Cancer Inst Inc | Inhibidores de factores de transcripción y usos. |
RU2016122654A (ru) | 2013-11-08 | 2017-12-14 | Дана-Фарбер Кэнсер Инститьют, Инк. | Комбинированная терапия злокачественной опухоли с использованием ингибиторов бромодоменового и экстратерминального (вет) белка |
WO2015117087A1 (en) | 2014-01-31 | 2015-08-06 | Dana-Farber Cancer Institute, Inc. | Uses of diazepane derivatives |
WO2015117053A1 (en) | 2014-01-31 | 2015-08-06 | Dana-Farber Cancer Institute, Inc. | Diaminopyrimidine benzenesulfone derivatives and uses thereof |
CN106456653A (zh) | 2014-02-28 | 2017-02-22 | 腾沙治疗公司 | 高胰岛素血症相关病症的治疗 |
CN106715437A (zh) | 2014-08-08 | 2017-05-24 | 达纳-法伯癌症研究所股份有限公司 | 二氮杂环庚烷衍生物及其用途 |
EP3177147A4 (en) | 2014-08-08 | 2018-01-24 | Dana-Farber Cancer Institute, Inc. | Dihydropteridinone derivatives and uses thereof |
KR20170068597A (ko) | 2014-10-27 | 2017-06-19 | 텐샤 세러퓨틱스 인코포레이티드 | 브로모도메인 저해제 |
AU2016276963C1 (en) | 2015-06-12 | 2021-08-05 | Dana-Farber Cancer Institute, Inc. | Combination therapy of transcription inhibitors and kinase inhibitors |
AU2016319116B2 (en) | 2015-09-11 | 2020-10-01 | Dana-Farber Cancer Institute, Inc. | Cyano thienotriazolodiazepines and uses thereof |
SG10202007099TA (en) | 2015-09-11 | 2020-08-28 | Dana Farber Cancer Inst Inc | Acetamide thienotriazoldiazepines and uses thereof |
KR20180081809A (ko) | 2015-11-25 | 2018-07-17 | 다나-파버 캔서 인스티튜트 인크. | 2가 브로모도메인 억제제 및 그의 용도 |
CN105541931B (zh) * | 2016-01-07 | 2018-08-17 | 江西师范大学 | 一种氟代糖苷衍生物及其制备方法 |
EP3717025B1 (en) * | 2017-12-01 | 2021-11-03 | UCB Biopharma SRL | Imaging agents |
CN111039853B (zh) * | 2019-12-26 | 2023-02-14 | 安徽大学 | 一种可用于光声成像和光热治疗的铁配合物及其制备方法和用途 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69809063T2 (de) * | 1997-08-04 | 2003-06-12 | Taisho Pharmaceutical Co Ltd | Aryloxyanilin-derivate |
JP2000001476A (ja) * | 1998-06-15 | 2000-01-07 | Taisho Pharmaceut Co Ltd | アリールオキシ含窒素アリールアミン誘導体 |
JP2004231647A (ja) * | 2003-01-10 | 2004-08-19 | Natl Inst Of Radiological Sciences | フェニルオキシアニリン誘導体 |
US6870069B2 (en) * | 2003-01-10 | 2005-03-22 | National Institute Of Radiological Sciences | Phenyloxyaniline derivatives |
GB0329716D0 (en) * | 2003-12-23 | 2004-01-28 | Amersham Plc | Radical trap |
GB0407952D0 (en) * | 2004-04-08 | 2004-05-12 | Amersham Plc | Fluoridation method |
US8644910B2 (en) * | 2005-07-19 | 2014-02-04 | Biosensors International Group, Ltd. | Imaging protocols |
DE102005055524B4 (de) * | 2005-11-22 | 2013-02-07 | BEGO Bremer Goldschlägerei Wilh. Herbst GmbH & Co. KG | Verfahren, Vorrichtung und System zur Herstellung eines keramischen Formkörpers |
US20080293969A1 (en) * | 2005-11-22 | 2008-11-27 | Ge Healthcare Limited | 18F-Labeled Daa Analogues and Method of Labeling These Analogues as Positron Emission Tomography (Pet) Tracers For Imaging Peripheral Benzodiazepine Receptors |
GB0525949D0 (en) * | 2005-12-21 | 2006-02-01 | Hammersmith Imanet Ltd | Pet radiotracers |
JP5916039B2 (ja) * | 2006-06-21 | 2016-05-11 | ジーイー・ヘルスケア・リミテッド | 放射性医薬品製品 |
WO2010015340A1 (en) * | 2008-08-06 | 2010-02-11 | Bayer Schering Pharma Aktiengesellschaft | Daa-pyridine as peripheral benzodiazepine receptor ligand for diagnostic imaging and pharmaceutical treatment |
-
2009
- 2009-07-25 WO PCT/EP2009/005399 patent/WO2010015340A1/en active Application Filing
- 2009-08-03 TW TW098126076A patent/TW201010734A/zh unknown
- 2009-08-05 JP JP2011521474A patent/JP2011529929A/ja active Pending
- 2009-08-05 CN CN200980130507.6A patent/CN102112448B/zh not_active Expired - Fee Related
- 2009-08-05 EA EA201100301A patent/EA018650B1/ru not_active IP Right Cessation
- 2009-08-05 UY UY0001032037A patent/UY32037A/es not_active Application Discontinuation
- 2009-08-05 NZ NZ590923A patent/NZ590923A/xx not_active IP Right Cessation
- 2009-08-05 AU AU2009278279A patent/AU2009278279B2/en not_active Ceased
- 2009-08-05 PE PE2011000123A patent/PE20110226A1/es not_active Application Discontinuation
- 2009-08-05 US US13/057,215 patent/US20110200535A1/en not_active Abandoned
- 2009-08-05 MX MX2011001406A patent/MX2011001406A/es not_active Application Discontinuation
- 2009-08-05 KR KR1020117005160A patent/KR20110041559A/ko not_active Application Discontinuation
- 2009-08-05 WO PCT/EP2009/005651 patent/WO2010015387A1/en active Application Filing
- 2009-08-05 BR BRPI0917099A patent/BRPI0917099A2/pt not_active IP Right Cessation
- 2009-08-05 AR ARP090102997A patent/AR073263A1/es not_active Application Discontinuation
- 2009-08-05 EP EP09777654.6A patent/EP2321279B1/en not_active Not-in-force
- 2009-08-05 CA CA2733105A patent/CA2733105A1/en not_active Abandoned
-
2011
- 2011-01-12 IL IL210597A patent/IL210597A0/en unknown
- 2011-02-04 CR CR20110064A patent/CR20110064A/es unknown
- 2011-02-04 DO DO2011000046A patent/DOP2011000046A/es unknown
- 2011-02-04 SV SV2011003830A patent/SV2011003830A/es not_active Application Discontinuation
- 2011-02-04 CO CO11013225A patent/CO6351715A2/es not_active Application Discontinuation
- 2011-02-04 CL CL2011000237A patent/CL2011000237A1/es unknown
- 2011-02-04 EC EC2011010808A patent/ECSP11010808A/es unknown
- 2011-03-04 ZA ZA2011/01700A patent/ZA201101700B/en unknown
Also Published As
Publication number | Publication date |
---|---|
CA2733105A1 (en) | 2010-02-11 |
WO2010015387A1 (en) | 2010-02-11 |
CN102112448A (zh) | 2011-06-29 |
CR20110064A (es) | 2011-03-30 |
SV2011003830A (es) | 2011-05-20 |
EP2321279B1 (en) | 2014-07-02 |
DOP2011000046A (es) | 2011-02-28 |
MX2011001406A (es) | 2011-03-21 |
CL2011000237A1 (es) | 2011-07-29 |
ECSP11010808A (es) | 2011-03-31 |
US20110200535A1 (en) | 2011-08-18 |
JP2011529929A (ja) | 2011-12-15 |
IL210597A0 (en) | 2011-03-31 |
AR073263A1 (es) | 2010-10-28 |
WO2010015340A1 (en) | 2010-02-11 |
EP2321279A1 (en) | 2011-05-18 |
CN102112448B (zh) | 2014-08-06 |
PE20110226A1 (es) | 2011-04-01 |
NZ590923A (en) | 2012-12-21 |
CO6351715A2 (es) | 2011-12-20 |
KR20110041559A (ko) | 2011-04-21 |
EA018650B1 (ru) | 2013-09-30 |
AU2009278279B2 (en) | 2014-04-17 |
AU2009278279A1 (en) | 2010-02-11 |
UY32037A (es) | 2010-03-26 |
ZA201101700B (en) | 2014-08-27 |
TW201010734A (en) | 2010-03-16 |
BRPI0917099A2 (pt) | 2016-02-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201100301A1 (ru) | Daa-пиридин в качестве лиганда периферического бензодиазепинового рецептора для диагностической визуализации и фармацевтического лечения | |
MX2021008976A (es) | Inhibidores marcados de antigeno prostatico especifico de membrama (psma), su uso como agentes formadores de imagenes y agentes farmaceuticos para el tratamiento de cancer de prostata. | |
EA201690862A1 (ru) | Соединения для позитронно-эмиссионной томографии | |
MX2013012793A (es) | Aminoacidos radiomarcados para imagen de diagnostico. | |
ECSP099610A (es) | Compuestos activos biológicamente marcados con fluoro-benzoilo 18f como agentes de diagnóstico por imágenes asi como precursores de benzotriazol-1-iloxi-benzoilo, 2,5-dioxo-pirrolidin-1-iloxi benzoilo y trimetilamonio benzoilo | |
NZ602291A (en) | Methods and apparatus for synthesizing imaging agents, and intermediates thereof | |
MX2013007699A (es) | Solucion de eluyente. | |
BR112015016585A2 (pt) | Compostos radiofarmacêuticos baseados em triazina, complexos de metal e composição farmacêutica compreendendo os referidos complexos | |
MX2011010295A (es) | Reactivos de radiomarcado y metodos. | |
EA201891444A1 (ru) | ЛИГАНДЫ mGluR2/3 ДЛЯ PET, МЕЧЕННЫЕ РАДИОАКТИВНЫМИ ИЗОТОПАМИ | |
AU2010332841A8 (en) | Prostate specific membrane antigen inhibitors | |
EA201290245A1 (ru) | Радиоактивно меченные pde10 лиганды | |
EA201300479A1 (ru) | Соединения для применения в визуализации, диагностике и/или лечении заболеваний центральной нервной системы | |
WO2010096426A8 (en) | Compounds, compositions, methods of synthesis, and methods of treatment | |
WO2009025914A3 (en) | Radiolabelled fluorobenzamide analogues, their synthesis and use in diagnostic imaging | |
SG194759A1 (en) | Novel precursors of glutamate derivatives | |
DOP2009000173A (es) | Marcacion radioactiva por fluoracion de aziridinas | |
BR112013006498A2 (pt) | composto | |
ATE521591T1 (de) | 11c-markierte benzyl-lactam-verbindungen und deren verwendung als bildgebungsmittel | |
MX2014007491A (es) | Agente de contraste para obtener imagenes de la perfusion miocardica. | |
MX2013010781A (es) | Compuestos para usarse en formacion de imagenes, diagnostico y/o tratamiento de enfermedades del sistema nervioso central. | |
NZ708849A (en) | Radiopharmaceutical products for diagnosis and therapy of adrenal carcinoma | |
WO2009033584A3 (en) | Diagnostic agents for positron emission imaging using f-18 radio-labeled amino-alcohols | |
BR112013006505A2 (pt) | composto, e, composição farmacêutica | |
BRPI0921795B8 (pt) | inibidores radiomarcados do transportador de glicina 1 e seu uso |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG MD TJ TM |
|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): RU |